Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • 4 hours ago

Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. At the time of this analysis, the BRAFTOVI combination regimen with FOLFIRI and cetuximab dem.

Business Wire • Jan 10, 2026

Healthy Returns: What to expect from pharma at the JPM conference

At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.

CNBC • Jan 9, 2026

Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product and patent cliff challenges could prevent a big bounce this year.

The Motley Fool • Jan 8, 2026

Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity

SAN FRANCISCO--(BUSINESS WIRE)-- #biotech--Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity.

Business Wire • Jan 8, 2026

Fed Governor Wants Huge Rate Cuts This Year: 5 High-Yield Dividend Stocks to Buy Today

Federal Reserve Governor Stephen Miran, whose term ends on January 31, argued in a recent Fox Business interview that the Fed should implement well over 100 basis points (or one percentage point) of rate cuts this year to support economic growth.

24/7 Wall Street • Jan 8, 2026

Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks

Some safe dividend stocks also offer high yields. Their payouts are high but aren't risky, and are backed by strong fundamentals.

The Motley Fool • Jan 8, 2026

This Could Be Key to Pfizer's Turnaround in 2026

Pfizer has been making deals in recent years to enhance its long-term growth potential. Last month, it reached a GLP-1 licensing deal with a China-based drug company.

The Motley Fool • Jan 7, 2026

Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio

PENSACOLA, Fla.--(BUSINESS WIRE)--At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, as more than 2,100 women pursue litigation alleging Pfizer failed to adequately warn patients despite long-standing knowledge of the risk. The hearing took place within days of the The US Food and Drug Administration (FDA) approving a label change to Pfizer's contr.

Business Wire • Jan 7, 2026

3 Drug Stocks to Buy at a Discount

Eli Lilly's GLP-1 weight loss drug is leading investors to award it a massive P/E ratio of 53. That's far higher than the pharmaceutical sector's average P/E ratio of about 30.

The Motley Fool • Jan 7, 2026